Who should attend:

• Clinical faculty from the University of Pittsburgh School of Pharmacy
• Clinical staff pharmacists employed by the University of Pittsburgh Medical Center and deployed throughout the hospital campus in unit based roles and centrally in the department of pharmacy's main pharmacy
• Student pharmacy interns currently working within the department of pharmacy
• Certified Pharmacy Technicians

Upon successful completion of this continuing pharmacy education program, the participant should be able to:

• Describe the pharmacokinetics of both NPH and Basal Insulin
• Identify the incidence of hypoglycemia with NPH vs Basal Insulin.
• Discuss the rate of glycemic control achieved with NPH vs Basal Insulin.

Pharmacy Continuing Education Credits This program is sponsored by the University of Pittsburgh Center for Continuing Education in the Health Sciences. The University of Pittsburgh Center for Continuing Education in the Health Sciences is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a Provider of continuing pharmacy education. The assigned universal program number(s) is 0481-0000-18-170-H04-P. This module is a webcast of an ACPE approved live presentation. The minimum credit awarded for this module (1 contact hour) is determined by the length of the entire live presentation inclusive of the post-test.

1. Piette JD, Heisler M, Wagner TH. Problems Paying Out-of-Pocket Medication Costs Among Older Adults With Diabetes. Diabetes Care. 2004;27(2):384-391
2. Cefalu WT, Dawes DE, Gavlak G, et al. Insulin Access and Affordability Working Group: Conclusions and Recommendations. Diabetes Care 2018;41:1299-1311
3. American Diabetes Association Standards of Medical Care In Diabetes – 2018. Diabetes Care. 2018;41(1):S1 – S159
4. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes algorithm – 2018 executive summary. Endocrine Practice. 2018;24(1):91-119
5. Humulin N (human insulin [rDNA origin] isophane suspension) [prescribing information] Indianapolis, IN. Eli Lily and Company. November 2018
6. Lantus (Insulin glargine) [prescribing information]. Bridgewater, NJ. July 2015
7. Basaglar (Insulin glargine) [prescribing information]. Indianapolis, IN. Eli Lily and Company. September 2018
8. Levemir (Insulin detemir) [prescribing information] Bagsvaerd, Denmark. February 2015.
9. Fiesselmann A, Wiesner T, Fleischmann H, et al. Real-world therapeutic benefits of patients on insulin glargine versus NPH insulin. Acta Diabetol. 2016;53:717-726
10. Strandberg AY, Khanfir H, Makimattila S, et al. Insulins NPH, glargine, and detemire, and risk of severe hypoglycemia among working-age adults. Annals of Medicine. 2017;49(4):357-364
11. Linong J, Puhong Z, Zhu D, et al. Comparative effectiveness and safety of different basal insulins in a real-world setting. Diabetes Obes Metab. 2017;19:1116-1126
12. Lipska KJ, Parker MM, Moffet HH, et al. Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin with Hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes. JAMA. 2018;320(1):53-62
13. NPH: Drug Information: Pricing: US. UpToDate. Waltham, MA: UpToDate Inc.
14. Insulin glargine. Drug Information: Pricing: US. UpToDate. Waltham, MA: UpToDate Inc.
15. Insulin detemir. Drug Information: Pricing: US. UpToDate. Waltham, MA: UpToDate Inc.
16. Insulin degludec. Drug Information: Pricing: US. UpToDate. Waltham, MA: UpToDate Inc.